GlaxoSmithKline and Pfizer to create a new world-leading, specialist HIV company
GlaxoSmithKline and Stiefel to create new world-leading specialist dermatology business
John K Smith opens his first drugstore in Philadelphia. John's younger brother, George, joins him in 1841 to form John K Smith & Co.
Thomas Beecham launches the Beecham's Pills laxative business in England. The laxative is to become widely successful.
Mahlon Kline joins Smith and Shoemaker - as John K Smith and Co had become - as a bookkeeper.
Beecham opens the world's first factory to be built solely for making medicines at St Helens in England.
Joseph Nathan, who left the UK to seek new business opportunities 20 years before, establishes a general trading company at Wellington in New Zealand - Joseph Nathan and Co - the foundation for the Glaxo company to be formed later.
Burroughs Wellcome & Company is established in London by American pharmacists Henry Wellcome and Silas Burroughs, four years after Joseph Nathan opened a London office.
Mahlon Kline took on additional responsibilities as a salesman and added many new and large accounts. He is rewarded when the company, Mahlon K Smith and Company, is renamed Smith, Kline and Company.
Thomas Beecham's company acquires headquarters on the corner of Silver Street and Water Street, St Helens, England. Two years later, the company's new factory in St Helens becomes the first in the area to have electricity.
Tabloid is registered as a Burroughs Wellcome and Company trademark to describe its compressed tablets.
Smith, Kline and Company acquires French, Richards and Company, providing a greater portfolio of consumer brands.
Glaxo is registered by Joseph Nathan and Co as a trademark for dried milk.
The Wellcome Tropical Research Laboratories open.
|1929 Smith, Kline and French Company is renamed Smith Kline and French Laboratories and becomes more focused on research.||1947
Glaxo Laboratories Ltd absorbs the Joseph Nathan company
and becomes the parent company. Glaxo is listed on the
London Stock Exchange.
||1936 Sir Henry Wellcome's will leaves sole ownership of The Wellcome Foundation Ltd to a UK medical research charity, today called the Wellcome Trust. Sir Henry Dale of Wellcome is awarded the Nobel Prize for Medicine for his work in the chemical transmission of nerve impulses.|
Glaxo acquires Allen and
|1982 SmithKline acquires Allergan, an eye and skincare business, and merges with Beckman Instruments Inc, a company specialising in diagnostics and measurement instruments and supplies. The company is renamed SmithKline Beckman.||1978 Through the acquisition of Meyer Laboratories Inc, Glaxo’s business in the US is started, to become Glaxo Inc from 1980. The broad-spectrum injectable antibiotic Zinacef (cefuroxime) is introduced by Glaxo.|
|1989 SmithKline Beckman and The Beecham Group plc merge to form SmithKline Beecham plc.||1995 Glaxo and Wellcome merge to form Glaxo Wellcome.|
|2000 GlaxoSmithKline formed through the merger of Glaxo Wellcome and SmithKline Beecham.|
April 16, 2009 GlaxoSmithKline
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company
GlaxoSmithKline plc (GSK) and Pfizer Inc (PFE) today announced they have entered into an agreement to create a new world-leading HIV company focused solely on research, development and commercialisation of HIV medicines. The new HIV business will be more sustainable and broader in scope than either company's individually, and will hold a 19% share of the growing market and have an industry-leading pipeline. GSK will initially hold an 85% equity interest in the new company and Pfizer will hold 15%.
Focused new business with
industry-leading HIV pipeline
The new company will have a broad product portfolio of 11 marketed products including market-leading therapies such as Combivir, Kivexa and Selzentry/Celsentri. Based on 2008 pro-forma results, this combined portfolio generated sales of approximately £1.6 billion and these revenues will provide the new company with financial stability and support investment in its pipeline.
The clear focus of the new business will be to invest in research and development of innovative HIV treatments and formulations that improve adherence and overcome resistance to the virus.
The company will have an industry-leading pipeline of 6 innovative and targeted medicines, including 4 compounds in phase II development. Altogether, the new company will have 17 molecules at its disposal to develop in fixed-dose combinations as possible new HIV treatments. The new company will contract R&D services directly from GSK and Pfizer to develop these medicines.
April 20, 2009
Stiefel to create new world-leading specialist dermatology
Stiefel, the world’s largest independent dermatology company, acquired by GSK in deal valued at up to $3.6 billion
New global business will have combined revenues of approximately $1.5 billion and robust new product pipeline
Significant step forward to grow and diversify GSK’s business, providing immediate new revenue and synergy opportunities
GlaxoSmithKline plc (GSK) and Stiefel Laboratories Inc. today announced that they have signed an agreement to create a new world-leading specialist dermatology business. Under the terms of the agreement GSK will acquire the total share capital of Stiefel for a cash consideration of $2.9 billion. GSK also expects to assume $0.4 billion of net debt upon closing. A potential further $0.3 billion cash payment is contingent on future performance. GSK’s existing prescription dermatological products will be combined with Stiefel’s and the new specialist global business will operate under the Stiefel identity within the GSK Group.
2015 年 12 月 18 日
18 December 2015
GSK’s global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb’s R&D HIV assets
GlaxoSmithKline plc today announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibb’s portfolio of preclinical and discovery stage HIV research assets.
Under the terms agreed in the two transactions, ViiV Healthcare will acquire:
These potential therapies have novel modes of action and would offer significant new treatment options to patients with HIV. In addition to being developed as standalone treatment options, these new assets complement ViiV Healthcare’s existing portfolio and therefore offer multiple opportunities for development as combination therapies.
The late-stage asset purchase comprises an upfront payment of $317 million, followed by development and first commercial sale milestones of up to $518M, and tiered royalties on sales.
The purchase of preclinical and discovery stage research assets comprises an upfront payment of $33 million, followed by development and first commercial sales milestones of up to $587M, and further consideration contingent on future sales performance.
David Redfern, Chief Strategy Officer at GSK and Chairman of ViiV Healthcare, said: “These acquisitions strengthen our leadership and innovation in HIV, one of our core areas of scientific research at GSK. The addition of two potential first-in-class late-stage treatments and several promising early clinical development programmes strengthens ViiV Healthcare’s pipeline and provides us with further new opportunities for growth.”
The two transactions are anticipated to complete independently during the first half of 2016, subject to necessary approvals, anti-trust and regulatory clearances.
GSK has been a leader in research and development of HIV since the 1980s, with the development of the world’s first breakthrough medicine for HIV patients, Retrovir (zidovudine). Development of new treatment options has continued, with Tivicay (dolutegravir) and Triumeq (dolutegravir/ abacavir/lamivudine), the most recent successful innovation. Research programmes are ongoing to develop new treatments and improve drug regimens, including the investigational long-acting integrase inhibitor, cabotegravir. Established in 2009, ViiV Healthcare is a specialist global HIV company, majority owned by GSK, with Pfizer and Shionogi as other shareholders.
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
31 March 2016 BBC News
GlaxoSmithKline to 'drop patents in poor
countries for better drug access'
Pharmaceutical firm GlaxoSmithKline has said it wants to make it easier for manufacturers in the world's poorest countries to copy its medicines.
The British company said it would not file patents in these countries.
Chief executive Sir Andrew Witty said he wanted to take a "graduated" approach to the company's "intellectual property" based on the wealth of nations around the globe.
Experts have described the plans as "brave and positive".
GSK hopes that by removing any fear of it filing for patent protection in poorer countries it will allow independent companies to make and sell versions of its drugs in those areas, thereby widening the public access to them.
'Clear and simple'
Sir Andrew said he hoped Africa would benefit most from the move.
In accordance with international guidelines set out by the United Nations and World Bank, the company has drawn up a list of 50 countries with a combined population of about 1 billion people, where it has said it will not file for patents.
In what GSK describes as lower middle income countries it will continue to file patents, but will grant licences to generic manufacturers in exchange for a "small royalty".
Sir Andrew added: "The changes we are setting out aim to make it as clear and simple as possible for generic manufacturers to make and supply versions of GSK medicines."
The company has said it also wants to put all its future cancer drugs into a Medicines Patent Pool in an effort to address what it described as "the increasing burden of cancer in developing countries".
医薬品特許プール（The Medicines Patent Pool、MPP）は、HIV治療へのアクセスを高め世界的に新しいイノベーションを促すため、UNITAIDによって2010年に創設された国連支援組織である。同財団は既存医薬品の低コスト版（ジェネリック薬）の製造に向けて、特許ライセンスを交渉するという新しい健康アプローチを提供し、メーカーと協力して子供に適した多剤混合薬（FDC）および製剤など、必要とする新しいテクノロジーの開発を奨励する。MPPは今日までに、医薬品メーカーが同組織からライセンスを受けた8種の抗レトロウイルスと6種のジェネリック薬でライセンス契約を結んでいる。
医薬品特許プール（The Medicines Patent Pool、MPP）とViiV Healthcare は2014年4月2日、HIV治療薬に関する新たなコラボレーションを発表し、成人および小児医療向けの新しい有望な抗レトロウイルス薬（ARV）、ドルテグラビル（dolutegravir、DTG）へのアクセス強化に対する2つの契約を結んだ。
The patents pool was established in 2010 and
has proved successful in accelerating access to treatments such as HIV,
tuberculosis and hepatitis C through voluntary licensing arrangements, which
allow generic versions of GSK's drugs to be made and distributed in poorer
Expanding the pool to include cancer drugs will "add to the wider contribution GSK makes to improve access to effective healthcare around the world", the company said.
Sir Andrew added: "The experience GSK has with the Medicines Patent Pool for Tivicay - our newest HIV medicine and one of our most commercially successful products - gives us confidence that increasing access, incentivising innovation appropriately and achieving business success can go hand in hand."
GSK said it would continue to seek full patent protection in richer parts of the world.
Prof Raymond Hill, former President of the British Pharmacological Society, said GSK's plans set a precedent for other major pharmaceutical companies to follow.
He said: "This is a brave and positive step towards broadening the access to important new medicines in the developing world.
"The impact of this move on the treatment of cancer and other diseases in each individual country will depend on whether there is a local adequate healthcare infrastructure that will allow the safe use of powerful new drugs in an appropriate group of patients.
"Many new cancer drugs are most valuable when used in sub-groups of patients identified by advanced diagnostic techniques that may not be available."
Prof Alan Boyd, from the Royal Colleges of Physicians, described the plans as "good news" and "significant"
He added: "Access to medicines for patients on a global basis is vital and it is good to see an innovative approach like this to ensure this happens."
Building on this perspective, GSK is evolving its graduated approach to filing and enforcing patents so that IP protection reflects a country’s economic maturity.
国連 開発援助委員会 （DAC)
GlaxoSmithKline (GSK) から抗がん剤製品群を買収するとともに、大衆薬事業はGSKの事業と統合し、GSK主体のJVとする。更にインフルエンザ以外のワクチン事業をGSKに売却する。
これにより、Novartisは事業を医薬品、Eye care製品、Generics の3つに絞り込む。
Horlicks は、粉末麦芽飲料のブランド。 就寝前に飲むと睡眠を促し、安眠できるとされる。旧イギリス植民地でポピュラーな飲み物。
GlaxoSmithKline plc today announces that it has reached an agreement with Novartis for the buyout of Novartis’ 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion). The Consumer Healthcare Joint Venture was formed as part of the three-part transaction between GSK and Novartis which was approved by shareholders in 2014. Last year, GSK’s Consumer Healthcare business reported sales of £7.8 billion and since 2015 sales have grown 4% on a 3 year CAGR basis (2015-2017 at 2014 CER) with an overall improvement in operating margins from 11.3% in 2015 to 17.7% in 2017.
Under the terms of the original transaction, Novartis has the right, exercisable from 2 March 2018 to 2 March 2035 to require GSK to purchase its stake (or specified tranches of it) in the Joint Venture. This put option, in both size and possible timing, creates inherent uncertainty for the Group’s capital planning. The new agreement to buy-out Novartis’ stake removes this uncertainty and improves the Group’s ability to plan allocation of capital to its other priorities.
As a result of the transaction, GSK’s shareholders will capture the full value of GSK’s Consumer Healthcare growth. With category-leading Power Brands, increased focus on science-based innovation and improved operational efficiencies, GSK Consumer Healthcare is well positioned to deliver sales growth, operating margin improvements and attractive returns. The business expects operating margins to approach ‘mid-20’s’ percentages by 2022 at 2017 CER.
The transaction is expected to be accretive to adjusted earnings in 2018 and thereafter, and is expected to strengthen operational cash flows. Together with the Group’s new launch opportunities and expected operational improvements, these financial benefits further support GSK’s increased confidence in its ability to deliver its 2020 outlooks and invest effectively in the Group’s other priorities.
The transaction is subject to approval by GSK shareholders as Novartis is treated as a related party under UK Listing Rules, and the Board intends to unanimously recommend that shareholders vote in favour of the transaction.
GSK is initiating a strategic review of Horlicks and its other consumer healthcare nutrition products to support funding of the transaction, and to drive increased focus on OTC and Oral Health categories. Combined sales of these products were approximately £550 million in 2017.
The majority of Horlicks and other nutrition products sales are generated in India, with the Horlicks range widely recognised as a portfolio of premium nutrition products. In India, these products are sold by GlaxoSmithKline Consumer Healthcare Ltd, a public company listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). The strategic review will include an assessment of GSK’s 72.5% shareholding in the company.
GSK expects the outcome of the strategic review to be concluded around the end of 2018. There can be no assurance that the review process will result in any transaction.
India remains a priority market for GSK investment and growth. The Consumer Healthcare business will continue to invest in growth opportunities for its OTC and Oral Health brands, such as Sensodyne and Eno. The Group is also actively investing in its Pharmaceutical and Vaccines businesses, including building new manufacturing capacity in Vemgal, Karnataka and Nashik.
Emma Walmsley, Chief Executive Officer, GSK said:
“The proposed transaction addresses one of our key capital allocation priorities and will allow GSK shareholders to capture the full value of one of the world’s leading Consumer Healthcare businesses. For the Group, the transaction is expected to benefit adjusted earnings and cash flows, helping us accelerate efforts to improve performance. Most importantly it also removes uncertainty and allows us to plan use of our capital for other priorities, especially pharmaceuticals R&D.”